Table 2.
Prognostic factors for overt hepatic encephalopathy in patients treated with transjugular intrahepatic portosystemic shunt
| Characteristics |
Univariate analysis
|
Multivariate analysis
|
||||
|
HR
|
95%CI
|
P value
|
HR
|
95%CI
|
P value
|
|
| Age (years) | 1.044 | (1.016-1.071) | 0.001a | 1.043 | (1.017-1.069) | 0.330 |
| Gender (male) | 1.207 | (0.629-2.316) | 0.572 | |||
| BMI (kg/m2) | 1.012 | (0.902-1.134) | 0.844 | |||
| Etiology (viral hepatitis/others) | 1.277 | (0.706-2.310) | 0.418 | |||
| Ascites (yes/no) | 0.845 | (0.465-1.536) | 0.580 | |||
| Child-Pugh score | 1.292 | (1.091-1.531) | 0.003a | 1.078 | (0.832-1.397) | 0.740 |
| MELD score | 1.137 | (1.074-1.203) | < 0.001a | 1.083 | (1.020-1.449) | 0.009a |
| NLR | 1.041 | (0.984-1.101) | 0.161 | |||
| TBIL (umol/L) | 1.033 | (1.014-1.053) | 0.001a | 1.029 | (1.000-1.058) | 0.768 |
| ALT (U/L) | 1.003 | (0.989-1.018) | 0.681 | |||
| AST (U/L) | 1.010 | (0.998-1.023) | 0.107 | |||
| Albumin (g/L) | 0.956 | (0.903-1.013) | 0.128 | |||
| Creatinine (umol/L) | 1.004 | (0.993-1.015) | 0.454 | |||
| Reduction of PPG (%) | 1.039 | (1.007-1.071) | 0.017a | 1.050 | (1.014-1.087) | 0.082 |
| PMA (HU) | 0.901 | (0.863-0.940) | < 0.001a | 0.930 | (0.889-0.974) | 0.002a |
| TPMT (mm/m) | 0.853 | (0.774-0.940) | 0.001a | 0.895 | (0.808-0.992) | 0.035a |
a
P < 0.05.
HE: Hepatic encephalopathy; BMI: Body mass index; MELD: Model for end-stage liver disease; NLR: Neutrophil-lymphocyte ratio; TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate transaminase; PPG: Portosystemic pressure gradient; PMA: Psoas muscle attenuation; TPMT: Transversal psoas muscle thickness; HU: Hounsfield units.